| |
| |
|
| Insider
Information: |
Stahl Neil |
| Relationship: |
EVP Research and Devel... |
| City: |
|
| State: |
|
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
50,999 |
|
|
Indirect Shares
|
10,439 |
|
|
| Direct
Value |
$50,235,035 |
|
|
|
Indirect Value
|
$10,282,624 |
|
|
| Total
Shares |
61,438 |
|
|
| Total
Value |
$60,517,659 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
5
|
|
Stock
price went up :
|
0
|
4
|
| Stock
price went down : |
0
|
1
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
4.0
|
| Percentage
Gain/Loss : |
0.0%
|
 57.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Regeneron Pharmaceuticals Inc |
REGN |
EVP Research and Devel... |
2024-02-26 |
50,999 |
2024-02-26 |
10,439 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
140 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 5 of 6
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2020-02-26 |
4 |
D |
$451.89 |
$6,620,640 |
D/D |
(14,651) |
21,729 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2020-02-26 |
4 |
OE |
$52.03 |
$1,300,750 |
D/D |
25,000 |
36,380 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2020-02-26 |
4 |
GD |
$0.00 |
$0 |
D/D |
750 |
20,979 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2020-02-27 |
4 |
AS |
$435.93 |
$4,680,460 |
D/D |
(10,349) |
11,380 |
0 |
% |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2020-04-13 |
4 |
D |
$511.56 |
$3,878,648 |
D/D |
(7,582) |
16,877 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2020-04-13 |
4 |
OE |
$52.03 |
$680,500 |
D/D |
13,079 |
24,459 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2020-04-14 |
4 |
AS |
$517.99 |
$2,864,307 |
D/D |
(5,497) |
11,380 |
0 |
% |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2020-05-08 |
4 |
OE |
$52.03 |
$650,375 |
D/D |
12,500 |
23,880 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2020-05-08 |
4 |
D |
$560.67 |
$4,034,021 |
D/D |
(7,195) |
16,685 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2020-05-11 |
4 |
S |
$567.50 |
$3,021,289 |
D/D |
(5,305) |
11,380 |
0 |
% |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2020-12-09 |
4 |
A |
$0.00 |
$0 |
D/D |
1,688 |
24,715 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2021-02-25 |
4 |
GD |
$0.00 |
$0 |
D/D |
435 |
24,280 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2021-05-14 |
4 |
D |
$516.69 |
$18,073,300 |
D/D |
(34,979) |
41,801 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2021-05-14 |
4 |
OE |
$52.03 |
$7,815,575 |
D/D |
52,500 |
49,005 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2021-05-17 |
4 |
S |
$518.63 |
$9,101,460 |
D/D |
(17,521) |
24,280 |
0 |
% |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2021-11-29 |
4 |
GD |
$0.00 |
$0 |
D/D |
4,605 |
28,809 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2021-11-29 |
4 |
GA |
$0.00 |
$0 |
I/I |
4,605 |
4,605 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2021-12-03 |
4 |
OE |
$179.13 |
$12,986,925 |
D/D |
72,500 |
101,309 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2021-12-03 |
4 |
D |
$632.45 |
$31,845,122 |
D/D |
(50,352) |
50,957 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2021-12-08 |
4 |
A |
$0.00 |
$0 |
D/D |
2,926 |
53,883 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2021-12-11 |
4 |
D |
$664.34 |
$500,248 |
D/D |
(753) |
53,130 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2022-02-18 |
4 |
GD |
$0.00 |
$0 |
D/D |
335 |
52,795 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2022-08-04 |
4 |
OE |
$270.43 |
$25,690,850 |
D/D |
95,000 |
147,795 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2022-08-04 |
4 |
D |
$613.00 |
$43,656,634 |
D/D |
(71,218) |
76,577 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2022-08-05 |
4 |
S |
$606.78 |
$14,569,134 |
D/D |
(23,782) |
52,795 |
0 |
% |
|
140 Records found
|
|
Page 5 of 6 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
